NCT04379076 (ILIAD-7-UK) is a Phase 2 clinical trial of Interleukin-7 in COVID-19, sponsored by Revimmune.

Who is sponsoring NCT04379076?

NCT04379076 is sponsored by Revimmune.

What drugs are being tested in NCT04379076?

Interventions in NCT04379076: Interleukin-7, Placebos.

What condition does NCT04379076 study?

NCT04379076 studies COVID-19, Lymphocytopenia.

Is NCT04379076 still recruiting?

NCT04379076 is currently terminated. Last updated 7 April 2022.

Last reviewed 2022-04-07 · How we verify

NCT04379076: ILIAD-7-UK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort

Terminated Phase 2 Last updated 7 April 2022

What this trial tests

Phase 2 trial testing Interleukin-7 in COVID-19 in 35 participants. Terminated before completion.

Timeline

14 May 2020

Primary endpoint
28 February 2022

30 March 2022

Quick facts

Lead sponsor	Revimmune
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	35
Start date	14 May 2020
Primary completion	28 February 2022
Estimated completion	30 March 2022
Sites	13 locations across United Kingdom

Drugs / interventions tested

Interleukin-7 — full drug profile →
Placebos — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
Lymphocytopenia — all drugs for Lymphocytopenia →

Sponsor

Revimmune — full company profile →

Who can join

Adults 25 to 80, any sex, with COVID-19 or Lymphocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparison of the effects of CYT107 vs Placebo administered IM at 10µg/kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The signal pathways and treatment of cytokine storm in COVID-19.
Yang L, Xie X, Tu Z, Fu J, et al · · 2021 · cited 429× · PMID 34234112 · DOI 10.1038/s41392-021-00679-0
Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.
Remy KE, Mazer M, Striker DA, Ellebedy AH, et al · · 2020 · cited 244× · PMID 32687484 · DOI 10.1172/jci.insight.140329
SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential.
Neidleman J, Luo X, Frouard J, Xie G, et al · · 2020 · cited 171× · PMID 32839763 · DOI 10.1016/j.xcrm.2020.100081
T-cell responses and therapies against SARS-CoV-2 infection.
Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, et al · · 2021 · cited 158× · PMID 32935333 · DOI 10.1111/imm.13262
Engineering cytokine therapeutics.
Deckers J, Anbergen T, Hokke AM, de Dreu A, et al · · 2023 · cited 132× · PMID 37064653 · DOI 10.1038/s44222-023-00030-y
Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System.
Peng X, Ouyang J, Isnard S, Lin J, et al · · 2020 · cited 76× · PMID 33384690 · DOI 10.3389/fimmu.2020.596631
Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines.
Dhawan M, Rabaan AA, Fawarah MMA, Almuthree SA, et al · · 2023 · cited 36× · PMID 36679947 · DOI 10.3390/vaccines11010101
Host directed therapies: COVID-19 and beyond.
Tripathi D, Sodani M, Gupta PK, Kulkarni S. · · 2021 · cited 36× · PMID 34870156 · DOI 10.1016/j.crphar.2021.100058

Verify or expand the search:

Other trials of Interleukin-7

Trials testing the same drug.

NCT04927169 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) · Phase 2 · terminated
NCT04407689 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort · Phase 2 · terminated
NCT02797431 — Immune Reconstitution of Immunosuppressed Sepsis Patients · Phase 2 · terminated

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Revimmune trials

Trials by the same sponsor.

NCT04927169 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) · Phase 2 · terminated
NCT04426201 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) · Phase 2 · terminated
NCT04154826 — Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease · Phase 2 · terminated
NCT04442178 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) · Phase 2 · terminated
NCT04407689 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04379076 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Revimmune
Last refreshed: 7 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04379076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing